直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

Prosecution First Blog

New Guidelines for § 101: More Than the Same Old, Same Old

May 17, 2016

Authored and Edited by Christopher C. Johns; Adriana L. Burgy

On May 4, 2016, the USPTO issued a new set of guidelines relating to rejections under § 101. Entitled “Formulating a Subject Matter Eligibility Rejection and Evaluating the Applicant's Response to a Subject Matter Eligibility Rejection,” the memo follows the format of previous guidance – such as providing the proper analysis for rejections under § 101 and exhorting examiners to make a proper case of ineligibility by showing their work. (And, just as with previous guidance, the examining corps is supposed to receive guidance on this memo in the coming weeks.)

Along with this new memo, the USPTO also provided new examples relating to the life sciences. The examples provide further guidance relating to the “markedly different” and “significantly more” tests that have been found to provide enough substance for eligibility. The PTO was relatively generous in its examples. For example, the first example of the memo relates to vaccines for “Pigeon flu,” and provides seven example claims – five eligible under step 2A of the Mayo/Alice framework (as being “markedly different”), one eligible under step 2B (as providing a device that constitutes “significantly more” than the exception), and one ineligible (as lacking “markedly different characteristics” or anything “significantly more” than the exceptions). The USPTO also updated its list of “Subject Matter Eligibility Court Decisions.” This list includes a few new cases that had not been issued at the time of the July 2015 memorandum.

But the memo goes a bit further than earlier guidance, seemingly illustrating a shift in the PTO’s thinking in response to the demands of its stakeholders.

In response to the July 2015 Update, members of the public submitted comments that an examiner’s mere “opinion” that a claim is drawn to an abstract idea was insufficient grounds for a rejection under § 101. For example, both AIPLA and FICPI urged the Office to require examiners to make a proper case of ineligibility instead of providing unsupported conclusions. In this most recent memo, the USPTO stated that examiners should not go beyond the concepts similar to those found ineligible by the courts in their rejections. The memo also urges examiners to be “familiar” with any decision they allege shows the claims to be ineligible.

If you receive a rejection that misapplies the law or merely concludes, without evidence, that claims are ineligible, there are a couple of avenues one can take. Contact the examiner and conduct an interview to discuss the cited case law so you have an opportunity to show why the case law is not relevant to your claims. And, refer back to the guidelines where it demands that examiners stick to what the courts have decided. This two‑pronged attack may provide the means to overcome a rejection under § 101.

Tags

patent application, 35 U.S.C. § 101, patentable subject matter

Contacts

Christopher C. Johns
Partner
Washington, DC
+1 202 408 4155
Email
Adriana L. Burgy
Partner
Washington, DC
+1 202 408 4345
Email

Copyright © 2016 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. 


DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.

Related Insights

Lecture

IPIC/McGill Summer IP Course 2026: Understanding Trademarks

July 14, 2026

Montreal

Charitable

Bridges From School to Work Gala 2026

June 22, 2026

Washington, DC

Charitable

Banding Together 2026

June 18, 2026

Washington, DC

Lecture

Munich Licensing Summer Course 2026

June 18-19, 2026

Munich

Conference

IPBC Global 2026

June 15-17, 2026

San Diego

Conference

2026 Copyright Society Annual Meeting

June 14-16, 2026

Louisville

Conference

17th Summit on Biosimilars & Innovator Biologics

June 2-3, 2026

New York

Articles

Article_D.-Mass-Patent-Litigation-Update-October-2024

D. Mass. Patent Litigation Update: April 2026

June 1, 2026

At the PTAB Blog

Consistency Is Key – USPTO Issues Three New Informative Decisions

May 29, 2026

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP